Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bio-Techne Corporation (NASDAQ: TECH) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Bio-Techne’s life sciences business, which focuses on tools, bioactive reagents, diagnostics, and spatial biology products for research and clinical diagnostic communities.
Investors can review current reports on Form 8-K, where Bio-Techne discloses material events such as quarterly and annual financial results and the declaration of cash dividends. For example, recent 8-K filings reference press releases describing results of operations, financial condition, and dividend announcements. These documents help readers understand revenue trends, segment performance for the Protein Sciences and Diagnostics and Spatial Biology segments, and key corporate actions.
Bio-Techne’s proxy statements on Schedule 14A provide insight into corporate governance, board composition, executive compensation, and shareholder proposals. The company’s definitive proxy statement discusses its mission to improve the quality of life by catalyzing advances in science and medicine, outlines its four growth pillars, and describes how the board oversees strategy, risk, and sustainability initiatives, including greenhouse gas emission reduction commitments.
Annual and quarterly reports on Forms 10-K and 10-Q, when accessed through EDGAR, contain segment disclosures, risk factors, and management’s discussion and analysis relevant to Bio-Techne’s life science tools and diagnostics operations. Filings related to shareholder meetings also detail voting results on director elections, advisory votes on executive compensation, and ratification of the independent registered public accounting firm.
On Stock Titan, these TECH filings are supplemented with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand what changed and why it matters. Real-time updates from EDGAR, combined with structured access to 8-Ks, proxy statements, and other filings, make this page a useful resource for tracking Bio-Techne’s regulatory disclosures and governance information.
Bio-Techne Corporation reported net sales of $311.4 million for the quarter ended March 31, 2026, down 2% from a year earlier, as softer Protein Sciences demand outweighed growth in Diagnostics and Spatial Biology. Organic revenue declined 2%, with foreign currency adding 2% and the absence of a held-for-sale business subtracting 2%.
Despite lower sales, GAAP net earnings rose to $51.0 million from $22.6 million, helped by a sharp reduction in litigation charges and ongoing cost management. Diluted EPS was $0.32, up from $0.14. Reported gross margin was 66.9%, slightly below last year as product mix shifted, and adjusted gross margin was 70.4%.
Operating cash flow for the nine months reached $196.7 million, up from $189.4 million, supporting higher cash and cash equivalents of $209.8 million and enabling $146.0 million of debt repayment, reducing long-term debt to $200.0 million. Segment operating margins remained strong at 44.2% for Protein Sciences and improved to 12.1% for Diagnostics and Spatial Biology, reflecting restructuring benefits and the Exosome Diagnostics divestiture.
Bio-Techne Corporation reported net sales of $311.4 million for the quarter ended March 31, 2026, down 2% from a year earlier, as softer Protein Sciences demand outweighed growth in Diagnostics and Spatial Biology. Organic revenue declined 2%, with foreign currency adding 2% and the absence of a held-for-sale business subtracting 2%.
Despite lower sales, GAAP net earnings rose to $51.0 million from $22.6 million, helped by a sharp reduction in litigation charges and ongoing cost management. Diluted EPS was $0.32, up from $0.14. Reported gross margin was 66.9%, slightly below last year as product mix shifted, and adjusted gross margin was 70.4%.
Operating cash flow for the nine months reached $196.7 million, up from $189.4 million, supporting higher cash and cash equivalents of $209.8 million and enabling $146.0 million of debt repayment, reducing long-term debt to $200.0 million. Segment operating margins remained strong at 44.2% for Protein Sciences and improved to 12.1% for Diagnostics and Spatial Biology, reflecting restructuring benefits and the Exosome Diagnostics divestiture.
FMR LLC reports beneficial ownership of 7,859,928.33 shares of BIO-TECHNE CORP common stock, representing 5.0% of the class as of 03/31/2026. The filing states FMR LLC has sole dispositive power for 7,859,928.33 shares and discloses related signatures and a Power of Attorney reference.
FMR LLC reports beneficial ownership of 7,859,928.33 shares of BIO-TECHNE CORP common stock, representing 5.0% of the class as of 03/31/2026. The filing states FMR LLC has sole dispositive power for 7,859,928.33 shares and discloses related signatures and a Power of Attorney reference.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corporation reported mixed third quarter fiscal 2026 results. Net sales were $311.4 million, down 2% year over year, with organic revenue also declining 2% as prior-year GMP fast-track orders and timing of large Commercial Supply shipments weighed on growth.
GAAP earnings improved sharply, with diluted EPS rising to $0.32 from $0.14, driven by a 95% increase in GAAP operating income to $75.5 million and a higher 24.2% operating margin helped by profitability initiatives and the Exosome Diagnostics divestiture. On a non-GAAP basis, adjusted EPS slipped to $0.53 from $0.56 and adjusted operating margin eased to 34.2% from 34.9%.
The Protein Sciences segment posted revenue of $226.2 million, down 1%, with organic revenue down 4%, while Diagnostics and Spatial Biology revenue declined 4% to $85.6 million but delivered 3% organic growth and margin expansion. The company ended the period with $209.8 million in cash and equivalents and reduced long-term debt to $200 million. The Board declared a quarterly cash dividend of $0.08 per share, payable May 29, 2026 to shareholders of record on May 18, 2026.
Bio-Techne Corp executive Steven C. Crouse reported routine equity compensation activity involving company stock. On May 1, 2026, he exercised 794 Restricted Stock Units, which converted into an equal number of Bio-Techne common shares.
To cover tax obligations, 311 common shares were disposed of through a tax-withholding transaction, a non-market event that does not represent an open-market sale. Following these transactions, Crouse directly holds 6,688 shares of common stock, alongside multiple option and restricted stock unit awards that vest over several future dates.
Bio-Techne Corp reports that Vanguard Capital Management beneficially owns 11,559,571 shares of Common Stock, representing 7.38% of the class. The filing states Vanguard exercises sole dispositive power over 11,559,571 shares and sole voting power over 1,379,862 shares. The filing attributes ownership to Vanguard Capital Management and affiliated Vanguard entities per SEC Release No. 34-39538.
Bio-Techne Corp Chief Executive Officer Kim Kelderman reported compensation-related equity activity, not open-market trading. On April 22, 2026, Kelderman exercised stock options to acquire 11,344 shares of Bio-Techne common stock, while 1,363 shares were disposed of to cover tax obligations at $58.58 per share. This left Kelderman with 63,058 common shares held directly after these transactions.
The filing also lists substantial remaining equity incentives, including multiple tranches of stock options and restricted stock units tied to vesting schedules and performance goals, with option exercise prices ranging from $47.60 to $120.46 and expirations extending to August 15, 2035.
Bio-Techne Corporation CFO James Hippel reported routine equity compensation activity. On April 22, 2026, he exercised stock options to acquire 62,000 shares of common stock at an exercise price of $47.60 per share. In a related F-code tax-withholding disposition, 56,097 shares of common stock were delivered at $58.58 per share to cover obligations. Following these transactions, Hippel directly owned 204,722 Bio-Techne common shares and retained substantial unexercised stock options and restricted stock units with vesting schedules extending through 2028.
Bio-Techne Corp Chief Executive Officer Kim Kelderman exercised stock options for 36,500 shares of common stock at an exercise price of $47.60 per share. The options were fully exercisable and converted into an equal number of common shares.
To cover tax obligations tied to this transaction, 32,088 shares of common stock were withheld at a price of $58.66 per share, a non-market tax-withholding disposition. After these transactions, Kelderman directly owns 53,077 common shares and retains substantial unexercised stock options and restricted stock units that vest over multiple future dates.
Bio-Techne Corp senior vice president and general counsel Shane Bohnen reported routine equity compensation activity. On April 3, 2026, he exercised restricted stock units into 2,259 shares of common stock. Of these, 740 shares were withheld at $53.13 per share to cover tax obligations, leaving him with 5,904 common shares held directly. He also continues to hold multiple stock option and restricted stock unit awards that can convert into additional Bio-Techne common shares over time.
The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting that it beneficially owns 0 shares (0%) of Bio‑Techne Corp common stock. The filing states an internal realignment effective January 12, 2026 led certain Vanguard subsidiaries to report separately, and the filing is signed on March 26, 2026.
The disclosure lists Vanguard's principal business office in Malvern, Pennsylvania, and confirms no sole or shared voting or dispositive power over the reported shares.